Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,739 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy.
Koido S, Kan S, Yoshida K, Yoshizaki S, Takakura K, Namiki Y, Tsukinaga S, Odahara S, Kajihara M, Okamoto M, Ito M, Yusa S, Gong J, Sugiyama H, Ohkusa T, Homma S, Tajiri H. Koido S, et al. Among authors: sugiyama h. Anticancer Res. 2014 Nov;34(11):6353-61. Anticancer Res. 2014. PMID: 25368235
The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells.
Li H, Oka Y, Tsuboi A, Yamagami T, Miyazaki T, Yusa S, Kawasaki K, Kishimoto Y, Asada M, Nakajima H, Kanato K, Nishida S, Masuda T, Murakami M, Hosen N, Kawakami M, Ogawa H, Melchers F, Kawase I, Oji Y, Sugiyama H. Li H, et al. Among authors: sugiyama h. Int J Hematol. 2003 Jun;77(5):463-70. doi: 10.1007/BF02986614. Int J Hematol. 2003. PMID: 12841384
Overexpression of the Wilms' tumor gene WT1 in esophageal cancer.
Oji Y, Yano M, Nakano Y, Abeno S, Nakatsuka S, Ikeba A, Yasuda T, Fujiwara Y, Takiguchi S, Yamamoto H, Fujita S, Kanato K, Ito K, Jomgeow T, Kawakami M, Tsuboi A, Shirakata T, Nishida S, Hosen N, Oka Y, Aozasa K, Monden M, Sugiyama H. Oji Y, et al. Among authors: sugiyama h. Anticancer Res. 2004 Sep-Oct;24(5B):3103-8. Anticancer Res. 2004. PMID: 15510596 Free article.
Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy.
Ohno S, Kyo S, Myojo S, Dohi S, Ishizaki J, Miyamoto K, Morita S, Sakamoto J, Enomoto T, Kimura T, Oka Y, Tsuboi A, Sugiyama H, Inoue M. Ohno S, et al. Among authors: sugiyama h. Anticancer Res. 2009 Nov;29(11):4779-84. Anticancer Res. 2009. PMID: 20032435 Free article. Clinical Trial.
A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination.
Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Tanaka-Harada Y, Hosen N, Nishida S, Shirakata T, Nakajima H, Tatsumi N, Hashimoto N, Taguchi T, Ueda S, Nonomura N, Takeda Y, Ito T, Myoui A, Izumoto S, Maruno M, Yoshimine T, Noguchi S, Okuyama A, Kawase I, Oji Y, Sugiyama H. Fujiki F, et al. Among authors: sugiyama h. Anticancer Res. 2010 Jun;30(6):2247-54. Anticancer Res. 2010. PMID: 20651376
Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response.
Takahara A, Koido S, Ito M, Nagasaki E, Sagawa Y, Iwamoto T, Komita H, Ochi T, Fujiwara H, Yasukawa M, Mineno J, Shiku H, Nishida S, Sugiyama H, Tajiri H, Homma S. Takahara A, et al. Among authors: sugiyama h. Cancer Immunol Immunother. 2011 Sep;60(9):1289-97. doi: 10.1007/s00262-011-1033-3. Epub 2011 May 24. Cancer Immunol Immunother. 2011. PMID: 21607557 Free PMC article.
2,739 results